Výsledky vyhledávání - John E. Godwin

  • Zobrazuji výsledky 1 - 18 z 18
Upřesnit hledání
  1. 1
    Hypoplastic myelodysplastic syndrome

    Hypoplastic myelodysplastic syndrome Autor Sucha Nand, John E. Godwin

    Vydáno 1988
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  2. 2
    Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

    Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis Autor Sucha Nand, Wendy Stock, John E. Godwin, Susan G. Fisher

    Vydáno 1996
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  3. 3
    Cetuximab in Refractory Skin Cancer Treatment

    Cetuximab in Refractory Skin Cancer Treatment Autor Sini Kalapurakal, James Malone, K. Thomas Robbins, Lucinda Buescher, John E. Godwin, Krishna Rao

    Vydáno 2012
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  4. 4
    Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/efflux+ and MDR1+/efflux- cases

    Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discorda... Autor CP Leith, IM Chen, KJ Kopecky, FR Appelbaum, DR Head, John E. Godwin, JK Weick, CL Willman

    Vydáno 1995
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  5. 5
    A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia

    A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia Autor Sucha Nand, Megan Othus, John E. Godwin, Cheryl L. Willman, Thomas H. Norwood, Dianna S. Howard, Steven Coutré, Harry P. Erba, Frederick R. Appelbaum

    Vydáno 2013
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  6. 6
    Age and acute myeloid leukemia

    Age and acute myeloid leukemia Autor Frederick R. Appelbaum, Holly Gundacker, David R. Head, Marilyn L. Slovak, Cheryl L. Willman, John E. Godwin, Jeanne E. Anderson, Stephen H. Petersdorf

    Vydáno 2006
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  7. 7
    A Double-Blind Placebo-Controlled Trial of Granulocyte Colony-Stimulating Factor in Elderly Patients With Previously Untreated Acute Myeloid Leukemia: A Southwest Oncology Group Study (9031)

    A Double-Blind Placebo-Controlled Trial of Granulocyte Colony-Stimulating Factor in Elderly Patients With Previously Untreated Acute Myeloid Leukemia: A Southwest Oncology Group St... Autor John E. Godwin, Kenneth J. Kopecky, David R. Head, Cheryl L. Willman, Catherine P. Leith, Harry E. Hynes, Stanley P. Balcerzak, Frederick R. Appelbaum

    Vydáno 1998
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  8. 8
    Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome

    Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome Autor Azra Raza, Naomi Galili, Scott E. Smith, John E. Godwin, Jeffrey E. Lancet, Magda Melchert, Marsha Jones, James Keck, Lisa Meng, Gail L. Brown, Alan F. List

    Vydáno 2009
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  9. 9
    Declining rates of treatment-related mortality in patients with newly diagnosed AML given ‘intense’ induction regimens: a report from SWOG and MD Anderson

    Declining rates of treatment-related mortality in patients with newly diagnosed AML given ‘intense’ induction regimens: a report from SWOG and MD Anderson Autor Megan Othus, Hagop M. Kantarjian, Stephen H. Petersdorf, Farhad Ravandi, John E. Godwin, Jorge E. Cortés, Sherry Pierce, Harry P. Erba, S. Faderl, F R Appelbaum, Elihu H. Estey

    Vydáno 2013
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  10. 10
    Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report

    Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report Autor Fabiana Ostronoff, Megan Othus, Phoenix A. Ho, Matthew A. Kutny, Daniel E. Geraghty, Stephen H. Petersdorf, John E. Godwin, Cheryl L. Willman, Jerald P. Radich, F. R. Appelbaum, Derek L. Stirewalt, Soheil Meshinchi

    Vydáno 2012
    Získat plný text
    Carta
    Přidat do oblíbených
    Uloženo v:
  11. 11
    Histone Deacetylase Inhibitor Romidepsin Has Differential Activity in Core Binding Factor Acute Myeloid Leukemia

    Histone Deacetylase Inhibitor Romidepsin Has Differential Activity in Core Binding Factor Acute Myeloid Leukemia Autor Olatoyosi Odenike, Serhan Alkan, Dorie Sher, John E. Godwin, Dezheng Huo, Stephen J. Brandt, Margaret Green, Jingping Xie, Yanming Zhang, David H. Vesole, Patrick J. Stiff, James R. Wright, Richard A. Larson, Wendy Stock

    Vydáno 2008
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  12. 12
    Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines

    Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines Autor Christiane Houde, Yulin Li, Lynda L. Song, Kevin Barton, Qing Zhang, John E. Godwin, Sucha Nand, Amir A. Toor, Serhan Alkan, N Smadja, Hervé Avet‐Loiseau, Carmen Sílvia Passos Lima, Lucio Miele, Lionel Coignet

    Vydáno 2004
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  13. 13
    Urelumab alone or in combination with rituximab in patients with relapsed or refractory B‐cell lymphoma

    Urelumab alone or in combination with rituximab in patients with relapsed or refractory B‐cell lymphoma Autor John M. Timmerman, Charles Herbaux, Vincent Ribrag, Andrew D. Zelenetz, Roch Houot, Sattva S. Neelapu, Theodore F. Logan, Izidore S. Lossos, Walter J. Urba, Gilles Salles, Radhakrishnan Ramchandren, Caron A. Jacobson, John E. Godwin, Cecilia Carpio, Deanne Lathers, Yali Liu, Jaclyn Neely, Satyendra Suryawanshi, Yoshinobu Koguchi, Ronald Levy

    Vydáno 2020
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  14. 14
    Prognostic Significance of <i>NPM1</i> Mutations in the Absence of <i>FLT3</i>–Internal Tandem Duplication in Older Patients With Acute Myeloid Leukemia: A SWOG and UK National Cancer Research Institute/Medical Research Council Report

    Prognostic Significance of <i>NPM1</i> Mutations in the Absence of <i>FLT3</i>–Internal Tandem Duplication in Older Patients With Acute Myeloid Leukemia: A SWOG and UK National Can... Autor Fabiana Ostronoff, Megan Othus, Michelle Lazenby, Elihu H. Estey, Frederick R. Appelbaum, Anna Evans, John E. Godwin, Amanda Gilkes, Kenneth J. Kopecky, Alan K. Burnett, Alan F. List, Min Fang, Vivian G. Oehler, Stephen H. Petersdorf, Era L. Pogosova‐Agadjanyan, Jerald P. Radich, Cheryl L. Willman, Soheil Meshinchi, Derek L. Stirewalt

    Vydáno 2015
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  15. 15
    Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study

    Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study Autor Alison R. Sehgal, Daanish Hoda, Peter A. Riedell, Nilanjan Ghosh, Mehdi Hamadani, Gerhard Hildebrandt, John E. Godwin, Patrick M. Reagan, Nina D. Wagner‐Johnston, James Essell, Rajneesh Nath, Scott R. Solomon, Rebecca Champion, Edward Licitra, Suzanne Fanning, Neel K. Gupta, Victor A. Chow, Brenda Yuan, Zhi Yang, K. OGASAWARA, Jerill Thorpe, Leo I. Gordon

    Vydáno 2025
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  16. 16
    TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML

    TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML Autor Jayakumar Vadakekolathu, Catherine Lai, Stephen Reeder, S. Church, Tressa Hood, Anbarasu Lourdusamy, Michael P. Rettig, Ibrahim Aldoss, Anjali S. Advani, John E. Godwin, Matthew J. Wieduwilt, Martha Arellano, John Muth, Tung On Yau, Farhad Ravandi, Kendra Sweet, Heidi Altmann, Gemma A. Foulds, Friedrich Stölzel, Jan Moritz Middeke, Marilena Ciciarello, Antonio Curti, Peter J.M. Valk, Bob Löwenberg, Ivana Gojo, Martin Bornhäuser, John F. DiPersio, Jan K. Davidson-Moncada, Sergio Rutella

    Vydáno 2020
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  17. 17
    Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

    Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Synd... Autor Geoffrey L. Uy, John E. Godwin, Michael P. Rettig, Norbert Vey, Matthew C. Foster, Martha Arellano, David A. Rizzieri, Max S. Topp, Gerwin Huls, Bob Löwenberg, Giovanni Martinelli, Stefania Paolini, Fabio Ciceri, Matteo Giovanni Carrabba, Carmen Ballesteros‐Merino, Carlo Bifulco, Hélène Lelièvre, Ross La Motte‐Mohs, Daner Li, Jichao Sun, Kenneth Jacobs, Karen Spohn, Nadia Lonsdale, Kathy Tran, Jan Baughman, Michele Shannon, Bernard A. Fox, Ezio Bonvini, Jon M. Wigginton, Jan K. Davidson-Moncada, John F. DiPersio

    Vydáno 2017
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  18. 18
    Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

    Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia Autor Geoffrey L. Uy, Ibrahim Aldoss, Matthew C. Foster, Peter H. Sayre, Matthew J. Wieduwilt, Anjali S. Advani, John E. Godwin, Martha Arellano, Kendra Sweet, Ashkan Emadi, Farhad Ravandi, Harry P. Erba, Michael Byrne, Laura C. Michaelis, Max S. Topp, Norbert Vey, Fabio Ciceri, Matteo Giovanni Carrabba, Stefania Paolini, Gerwin Huls, Mojca Jongen‐Lavrencic, Martin Wermke, Patrice Chevallier, Emmanuel Gyan, Christian Récher, Patrick J. Stiff, Kristen Pettit, Bob Löwenberg, S. Church, Erica Anderson, Jayakumar Vadakekolathu, Marianne Santaguida, Michael P. Rettig, John Muth, Teia Curtis, Erin Fehr, Kuo Guo, Jian Zhao, Ouiam Bakkacha, Kenneth Jacobs, Kathy Tran, Patrick Kaminker, Maya Kostova, Ezio Bonvini, Roland B. Walter, Jan K. Davidson-Moncada, Sergio Rutella, John F. DiPersio

    Vydáno 2020
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:

Vyhledávací nástroje: